At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating High dose Aspirin & Vitamin D, High dose Aspirin, Vitamin D placebo, and 4 other interventions for Prostate Cancer. Completed, enrolled 104 participants across 7 sites.
Detailed Summary
To demonstrate the acceptability and feasibility of recruitment to a randomised chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate cancer.
Study Details
Timeline
Interventions
Aspirin 1 x 300mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Aspirin 1 x 300mg tablet daily \& Vitamin D placebo (8 drops).
Aspirin 1 x 100mg tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Aspirin 1 x 100mg tablet daily \& Vitamin D placebo 8 drops daily.
Aspirin 1 x 300mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).
Aspirin 1 x 100mg placebo tablet daily \& Vitamin D 4,000IU daily. (8 drops).